<DOC>
	<DOCNO>NCT01406704</DOCNO>
	<brief_summary>This study evaluate effect Rosiglitazone , insulin sensitizer alpha-lipoic acid , antioxidant patient pathologically prove NASH ( non-alcoholic steato-hepatitis ) .</brief_summary>
	<brief_title>Effects Rosiglitazone Alpha-lipoic Acid Patients With Pathologically Proved NASH</brief_title>
	<detailed_description>Duration : 24 week-intervention Study Group : Four arm - Control : intervention - Rosiglitazone : rosiglitazone ( 8 mg/day ) - alpha-lipoic acid : alpha-lipoic acid ( 1800 mg/day ) - Rosiglitazone/alpha-lipoic acid : combination rosiglitazone ( 8 mg/day ) alpha-lipoic acid ( 1800 mg/day )</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>patient pathologically prove NASH ( nonalcoholic steatohepatitis ) alcohol consumption &gt; 20g/day viral hepatitis B C autoimmune hepatitis Wilson 's disease hemochromatosis alpha1 antitrypsin deficiency breastfeed pregnant female subject plan become pregnant severe comorbid medical condition ( severe cardiac , pulmonary , renal psychological problem ) consent study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2004</verification_date>
</DOC>